MCID: OCL022
MIFTS: 50

Ocular Melanoma

Categories: Cancer diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Ocular Melanoma

MalaCards integrated aliases for Ocular Melanoma:

Name: Ocular Melanoma 12 74 52 54 15 17
Intraocular Melanoma 12 52
Malignant Melanoma of Eye 71
Melanoma of the Uvea 52
Melanoma of Eye 12
Uveal Melanoma 52
Eye Melanoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1752
UMLS 71 C0558356

Summaries for Ocular Melanoma

NIH Rare Diseases : 52 Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract . The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common. Each manifests with different clinical features and symptoms. Treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor , the age of the individual, and other factors.

MalaCards based summary : Ocular Melanoma, also known as intraocular melanoma, is related to malignant spindle cell melanoma and skin melanoma. An important gene associated with Ocular Melanoma is PDCD6 (Programmed Cell Death 6), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and PI3K-Akt signaling pathway. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and retina, and related phenotypes are cellular and homeostasis/metabolism

Disease Ontology : 12 An ocular cancer that has material basis in melanocytes and is located in the eye.

Wikipedia : 74 Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, or choroid... more...

Related Diseases for Ocular Melanoma

Diseases related to Ocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 419)
# Related Disease Score Top Affiliating Genes
1 malignant spindle cell melanoma 30.9 NRAS KIT CDKN2A
2 skin melanoma 30.8 NRAS MC1R KIT CDKN2A CD63
3 malignant peritoneal mesothelioma 30.3 CDKN2A BAP1
4 plasmacytoma 30.2 VEGFA IL2 CDKN2A
5 exanthem 30.2 VEGFA TNF KIT IL2
6 rubeosis iridis 30.1 VEGFA PLG
7 peritoneal mesothelioma 30.0 VEGFA CDKN2A BAP1
8 cystitis 29.9 VEGFA TNF KIT IL2
9 thymoma 29.9 VEGFA TNF KIT IL2 CDKN2A
10 melanoma, cutaneous malignant 1 29.8 TERT NRAS MC1R KIT CDKN2A BRCA2
11 neurofibroma 29.8 VEGFA S100B KIT CDKN2A
12 leiomyosarcoma 29.8 VEGFA S100B KIT CDKN2A
13 retinal ischemia 29.8 VEGFA TNF HSPA4
14 uveal disease 29.7 VEGFA TNF NRAS IL2 BAP1
15 lung cancer susceptibility 3 29.6 VEGFA TERT NRAS KIT CDKN2A AXL
16 meningioma, familial 29.5 VEGFA TERT CDKN2A BAP1
17 adenocarcinoma 29.4 VEGFA KIT CDKN2A BRCA2 AXL
18 endophthalmitis 29.4 VEGFA TNF PLG
19 ocular cancer 29.4 PLG MC1R IL2 CDKN2A BRCA2
20 conjunctivitis 29.3 TNF PLG IL2
21 basal cell carcinoma 29.1 VEGFA TNF TERT MC1R KIT IL2
22 glioblastoma multiforme 29.1 VEGFA TERT NRAS KIT IL2 CDKN2A
23 myelodysplastic syndrome 29.0 VEGFA TNF TERT NRAS KIT IL2
24 mucosal melanoma 29.0 VEGFA TERT NRAS KIT IL2 CDKN2A
25 leukemia, chronic myeloid 28.8 VEGFA NRAS KIT HSPA4 AXL
26 gastric adenocarcinoma 28.8 VEGFA TNF TERT NRAS KIT CDKN2A
27 melanoma 28.7 VEGFA TNF TERT S100B NRAS MC1R
28 lymphoma, non-hodgkin, familial 28.7 VEGFA TNF NRAS IL2 HSPA4 CDKN2A
29 pancreatic adenocarcinoma 28.6 VEGFA TNF TERT KIT IL2 CDKN2A
30 neuroblastoma 28.5 VEGFA TNF TERT NRAS KIT IL2
31 leukemia, acute myeloid 28.3 VEGFA TNF TERT NRAS KIT IL2
32 melanoma, uveal 28.2 VEGFA TERT S100B PTP4A3 PLG NRAS
33 hepatocellular carcinoma 27.8 VEGFA TNF TERT NRAS MAGEA3 MAGEA1
34 ovarian cancer 27.4 VEGFA TNF TERT PLG MAGEA1 KIT
35 lung cancer 26.5 VEGFA TNF TERT PLG NRAS MAGEA3
36 necrotic uveal melanoma 12.8
37 mixed cell uveal melanoma 12.5
38 spindle cell intraocular melanoma 12.4
39 tumor predisposition syndrome 11.9
40 bap1 tumor predisposition syndrome 11.9
41 uveal epithelioid cell melanoma 11.6
42 iris spindle cell melanoma 11.3
43 melanoma, cutaneous malignant 10 10.9
44 severe combined immunodeficiency 10.5
45 melphalan allergy 10.5 NRAS IL2
46 macular retinal edema 10.5
47 cervical adenoid cystic carcinoma 10.5 KIT CDKN2A
48 malignant dermis tumor 10.4 NRAS KIT
49 malignant skin fibrous histiocytoma 10.4 NRAS KIT
50 laryngeal small cell carcinoma 10.4 KIT CDKN2A

Graphical network of the top 20 diseases related to Ocular Melanoma:



Diseases related to Ocular Melanoma

Symptoms & Phenotypes for Ocular Melanoma

MGI Mouse Phenotypes related to Ocular Melanoma:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 AXL BAP1 BRCA2 CDKN2A HSPA4 IL2
2 homeostasis/metabolism MP:0005376 10.3 AXL BAP1 BRCA2 CD63 CDKN2A IL2
3 cardiovascular system MP:0005385 10.29 AXL BAP1 CDKN2A IL2 KIT MC1R
4 endocrine/exocrine gland MP:0005379 10.29 AXL BAP1 BRCA2 CDKN2A HSPA4 IL2
5 growth/size/body region MP:0005378 10.27 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
6 digestive/alimentary MP:0005381 10.26 BAP1 BRCA2 CD63 CDKN2A IL2 KIT
7 hematopoietic system MP:0005397 10.26 AXL BAP1 BRCA2 CDKN2A IL2 KIT
8 immune system MP:0005387 10.21 AXL BAP1 BRCA2 CDKN2A IL2 KIT
9 integument MP:0010771 10.14 AXL BAP1 BRCA2 CDKN2A KIT MC1R
10 mortality/aging MP:0010768 10.13 AXL BAP1 BRCA2 CDKN2A HSPA4 IL2
11 neoplasm MP:0002006 10.03 BAP1 BRCA2 CDKN2A IL2 KIT MC1R
12 liver/biliary system MP:0005370 10.02 AXL CDKN2A IL2 KIT NRAS PLG
13 no phenotypic analysis MP:0003012 9.81 BAP1 CDKN2A IL2 KIT MC1R NRAS
14 reproductive system MP:0005389 9.7 AXL BAP1 BRCA2 CDKN2A HSPA4 IL2
15 respiratory system MP:0005388 9.23 BAP1 CDKN2A IL2 KIT PLG TERT

Drugs & Therapeutics for Ocular Melanoma

Drugs for Ocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4 347396-82-1 459903
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3 Hormone Antagonists Phase 4
4 Hormones Phase 4
5 Triamcinolone diacetate Phase 4
6 triamcinolone acetonide Phase 4
7 glucocorticoids Phase 4
8 Triamcinolone hexacetonide Phase 4
9 Anti-Inflammatory Agents Phase 4
10
Melphalan Approved Phase 3 148-82-3 460612 4053
11
Bevacizumab Approved, Investigational Phase 3 216974-75-3
12
Fotemustine Investigational Phase 3 92118-27-9
13 Liver Extracts Phase 3
14 Immunologic Factors Phase 3
15 Immunosuppressive Agents Phase 3
16 Alkylating Agents Phase 3
17 Mitogens Phase 3
18 Endothelial Growth Factors Phase 3
19 Vaccines Phase 3
20
Sodium citrate Approved, Investigational Phase 2 68-04-2
21
Tamoxifen Approved Phase 2 10540-29-1 2733526
22
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
23
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
24 Ethiodized oil Approved, Investigational Phase 2 8008-53-5
25
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
26
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
27
Pasireotide Approved Phase 2 396091-73-9 9941444
28
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
29
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
30
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
31
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181 3911
32
Aluminum sulfate Approved Phase 2 10043-01-3
33
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
34
Pancrelipase Approved, Investigational Phase 2 53608-75-6
35
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
36
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
37
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
38
Acyclovir Approved Phase 2 59277-89-3 2022
39
Olaparib Approved Phase 2 763113-22-0 23725625
40
Iodine Approved, Investigational Phase 2 7553-56-2 807
41
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
42
Acetaminophen Approved Phase 2 103-90-2 1983
43
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
44
Cobalt Approved, Experimental Phase 2 7440-48-4 104729
45
Promethazine Approved, Investigational Phase 2 60-87-7 4927
46
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
47
Lenalidomide Approved Phase 2 191732-72-6 216326
48
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
49
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
50
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314

Interventional clinical trials:

(show top 50) (show all 169)
# Name Status NCT ID Phase Drugs
1 A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma Unknown status NCT00540930 Phase 4 Ranibizumab
2 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
3 Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma. Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
4 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
5 A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
6 A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
7 A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA Recruiting NCT01983748 Phase 3
8 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
9 A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma Recruiting NCT02678572 Phase 3
10 Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
11 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
12 Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
13 Randomized Phase III Study Of Adjuvant Immunization With The NA17.A2 And Melanoma Differentiation Peptites In HLA-A2 Patients With Primary Ocular Melanoma At High Risk Of Relapse Terminated NCT00036816 Phase 3
14 A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
15 Phase II Single-Center Study of Bevacizumab in Combination With Temozolomide in Patients With First-Line Metastatic Uveal Melanoma Unknown status NCT01217398 Phase 2 temozolomide
16 Randomized Phase II Study to Compare a Combination Therapy With Gemcitabine and Treosulfan Versus a Monotherapy as First-Line Chemotherapy for Patients With Metastatic Ocular Melanoma Unknown status NCT00168870 Phase 2 Gemcitabine;Treosulfan
17 A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
18 A Phase II Trial of Pyrazoloacridine (NSC 366140, IND 36325) in Metastatic Cutaneous and Ocular Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
19 Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma Completed NCT00085306 Phase 2
20 A Phase 2 Study Of Weekly Infusion Nab-paclitaxel (Paclitaxel Protein-bound Particles for Injectable Suspension) In Patients With Unresectable And Metastatic Uveal Melanoma Completed NCT00738361 Phase 2 nab-paclitaxel
21 Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
22 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
23 A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Completed NCT01551459 Phase 2 Dacarbazine;Sunitinib
24 A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma Completed NCT02363283 Phase 2 Glembatumumab Vedotin
25 Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance Completed NCT01100528 Phase 2 dacarbazine
26 Phase II Study of IMC-A12 in Metastatic Uveal Melanoma Completed NCT01413191 Phase 2
27 Immuno-embolization of Hepatic Artery With Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) Completed NCT00661622 Phase 2 GM-CSF
28 A Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma Completed NCT00506142 Phase 2 Marqibo® (vincristine sulfate liposomes injection)
29 Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
30 A Phase II Study of the HSP Inhibitor STA-9090 in Metastatic Ocular Melanoma Completed NCT01200238 Phase 2 STA-9090
31 A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
32 Open Label Phase II Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
33 A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
34 THE IPI - Multibasket Trial in Advanced Melanoma: Prospective Clinical Phase II Multibasket Study in Melanoma Patients With Advanced Disease (DeCOG MM-PAL11) Completed NCT01355120 Phase 2 Ipilimumab
35 Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
36 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan Followed by Temozolomide for Subjects With Unresectable Hepatic Metastases From Ocular Melanoma Completed NCT00062933 Phase 2
37 Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma Completed NCT00089206 Phase 2
38 A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma Completed NCT00027742 Phase 2 temozolomide
39 A Randomized Phase II Study of Oral Lenalidomide (Revlimid [TM]), an Antiangiogenic and Immunomodulatory Agent, in Subjects With Stage IV Ocular Melanoma Completed NCT00109005 Phase 2 Revlimid
40 An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
41 A Phase II Trial of an Intradermally Administered MART-1gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail for Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
42 Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma Completed NCT00089219 Phase 1, Phase 2
43 An Open-label Study Of MDX-010 In Combination With gp100 Peptides Emulsified With Montanide ISA 51 In The Treatment Of Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
44 A Randomized Phase II Trial of a Vaccine Combining Tyrosinase/gp100 Peptides Emulsified With Montanide ISA 51 With and Without Interleukin-12 for Patients With Resected Stages III and IV Melanoma Completed NCT00003339 Phase 2
45 A Phase II Study of Temozolomide, Thalidomide, and Lomustine in the Treatment of Advanced Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
46 Phase II Study of Pegylated Interferon and Thalidomide in Pretreated Metastatic Malignant Melanoma Completed NCT00238329 Phase 2 thalidomide
47 Study of the Modulatory Activity of an LHRH-Agonist (Leuprolide) on Melanoma Peptide Vaccines as Adjuvant Therapy in Melanoma Patients Completed NCT00254397 Phase 2 Leuprolide
48 A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide
49 A Phase II Randomized Trial of a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With Interleukin-12 With Alum or GM-CSF for Patients With Resected Stages IIB/C, III and IV Melanoma Completed NCT00031733 Phase 2 alum adjuvant
50 MDX-CTLA4 Combined With IL-2 for Patients With Metastatic Melanoma Completed NCT00058279 Phase 1, Phase 2

Search NIH Clinical Center for Ocular Melanoma

Genetic Tests for Ocular Melanoma

Anatomical Context for Ocular Melanoma

The Foundational Model of Anatomy Ontology organs/tissues related to Ocular Melanoma:

19
Eye

MalaCards organs/tissues related to Ocular Melanoma:

40
Eye, Liver, Retina, T Cells, Endothelial, Skin, Testes

Publications for Ocular Melanoma

Articles related to Ocular Melanoma:

(show top 50) (show all 1007)
# Title Authors PMID Year
1
Cancer-related diseases of the eye: the role of calcium and calcium-binding proteins. 61 54
15336963 2004
2
Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. 54 61
15326139 2004
3
Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study. 61 54
12883368 2003
4
BRCA2 mutations in a population-based series of patients with ocular melanoma. 61 54
12385017 2002
5
Expression of MAGE genes in ocular melanoma cell lines. 54 61
9220316 1997
6
Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. 61
32564137 2020
7
Gene Expression Profiling Prognostication of Posterior Uveal Melanoma: Does Size Matter? 61
32081600 2020
8
Bioresorbable, Miniaturized Porous Silicon Needles on a Flexible Water-Soluble Backing for Unobtrusive, Sustained Delivery of Chemotherapy. 61
32401016 2020
9
AAPM recommendations on medical physics practices for ocular plaque brachytherapy: Report of task group 221. 61
31883269 2020
10
Practice Patterns for the Treatment of Uveal Melanoma with Iodine-125 Plaque Brachytherapy: Ocular Oncology Study Consortium Report 5. 61
32509767 2020
11
Electrochemotherapy in 3D Ocular Melanoma Spheroids using a Customized Electrode. 61
32421010 2020
12
The Collaborative Ocular Melanoma Study Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma. 61
32200814 2020
13
Ocular melanoma incidence rates and trends in the United States, 2001-2016. 61
32350449 2020
14
Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort. 61
32321466 2020
15
The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: IV. Local Treatment Failure and Enucleation in the First 5 Years after Brachytherapy. COMS Report No. 19. 61
32200815 2020
16
Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: A population-based study. 61
31626886 2020
17
Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. 61
30924738 2020
18
Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study. 61
31425478 2020
19
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. 61
32087721 2020
20
Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization. 61
31686137 2020
21
Meta-analysis on the utility of radiotherapy for the treatment of Ocular Melanoma 61
31916427 2020
22
BRCA1-associated protein (BAP1)-inactivated melanocytic tumors. 61
31233225 2019
23
Experimental validation of a new COMS-like 24 mm eye plaque for the treatment of large ocular melanoma tumors. 61
31444131 2019
24
Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases from ocular melanoma. 61
31650973 2019
25
m6A modification suppresses ocular melanoma through modulating HINT2 mRNA translation. 61
31722709 2019
26
CHOROIDAL NEVUS IMAGING FEATURES IN 3,806 CASES AND RISK FACTORS FOR TRANSFORMATION INTO MELANOMA IN 2,355 CASES: The 2020 Taylor R. Smith and Victor T. Curtin Lecture. 61
30608349 2019
27
CHOROIDAL NEVUS TRANSFORMATION INTO MELANOMA PER MILLIMETER INCREMENT IN THICKNESS USING MULTIMODAL IMAGING IN 2355 CASES: The 2019 Wendell L. Hughes Lecture. 61
30883534 2019
28
Delivered dose changes in COMS plaque-based ocular brachytherapy arising from vitrectomy with silicone oil replacement. 61
31272841 2019
29
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). 61
31445199 2019
30
Clinical spectrum, treatment and outcomes of uveal melanoma in a tertiary centre. 61
31197380 2019
31
An improved treatment planning and quality assurance process for Collaborative Ocular Melanoma Study eye plaque brachytherapy. 61
31235445 2019
32
Multi-Modality Analysis Improves Survival Prediction in Enucleated Uveal Melanoma Patients. 61
31425584 2019
33
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. 61
31150059 2019
34
Complications and adverse events of plaque brachytherapy for ocular melanoma. 61
31523242 2019
35
Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. 61
31446147 2019
36
Comprehensive Characterization of the Human Endogenous Retrovirus HERV-K(HML-6) Group: Overview of Structure, Phylogeny, and Contribution to the Human Genome. 61
31167914 2019
37
Improvement of dose distribution in ocular brachytherapy with 125I seeds 20-mm COMS plaque followed to loading of choroidal tumor by gold nanoparticles. 61
31169211 2019
38
Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. 61
30767147 2019
39
Vitamin D receptors (VDR), hydroxylases CYP27B1 and CYP24A1 and retinoid-related orphan receptors (ROR) level in human uveal tract and ocular melanoma with different melanization levels. 61
31235702 2019
40
RELATIONSHIP OF CLINICAL FEATURES AND BASELINE TUMOR SIZE WITH GENE EXPRESSION PROFILE STATUS IN UVEAL MELANOMA: A Multi-institutional Study. 61
29578940 2019
41
Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy. 61
30763658 2019
42
Y90 Clinical Data Update: Cholangiocarcinoma, Neuroendocrine Tumor, Melanoma, and Breast Cancer Metastatic Disease. 61
31079715 2019
43
Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma. 61
30797699 2019
44
Natural killer cells and pigment epithelial-derived factor control the infiltrative and nodular growth of hepatic metastases in an Orthotopic murine model of ocular melanoma. 61
31117965 2019
45
Small choroidal melanoma: detection with multimodal imaging and management with plaque radiotherapy or AU-011 nanoparticle therapy. 61
30844944 2019
46
Epidemiological evidence of carcinogenicity of sunbed use and of efficacy of preventive measures. 61
30811691 2019
47
Skin cancer and welding. 61
30280417 2019
48
An Update on Mucosal Melanoma: Future Directions. 61
31032785 2019
49
A comparison of the shielding effectiveness of silicone oil vitreous substitutes when used with Palladium-103 and Iodine-125 eye plaques. 61
30554429 2019
50
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. 61
30651126 2019

Variations for Ocular Melanoma

Cosmic variations for Ocular Melanoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM84060431 GNA11 eye,uveal tract,malignant melanoma,ring c.626A>T p.Q209L 19:3118944-3118944 24

Expression for Ocular Melanoma

Search GEO for disease gene expression data for Ocular Melanoma.

Pathways for Ocular Melanoma

Pathways related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13 VEGFA TNF NRAS KIT IL2 HSPA4
2
Show member pathways
12.68 VEGFA TNF TERT NRAS KIT IL2
3
Show member pathways
12.54 TERT NRAS KIT CDKN2A BRCA2
4 12.07 VEGFA TNF NRAS CD63
5 12.07 TNF MAGEA3 KIT IL2 CD63
6 11.89 VEGFA TERT NRAS KIT IL2 CDKN2A
7 11.69 TNF TERT NRAS IL2 CDKN2A
8 11.6 TNF KIT IL2
9 11.56 TNF KIT IL2
10 11.53 VEGFA NRAS CDKN2A
11
Show member pathways
11.41 VEGFA TNF IL2
12 11.21 TNF IL2 CDKN2A
13 11.11 VEGFA TNF NRAS

GO Terms for Ocular Melanoma

Cellular components related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 VEGFA TNF S100B PLG KIT IL2
2 cell surface GO:0009986 9.1 VEGFA TNF PLG KIT CD63 AXL

Biological processes related to Ocular Melanoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.87 TNF NRAS KIT IL2
2 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.73 TNF PDCD6 CDKN2A
3 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.7 VEGFA TNF MAGEA3
4 positive regulation of protein kinase B signaling GO:0051897 9.67 TNF MC1R KIT AXL
5 positive regulation of kinase activity GO:0033674 9.63 KIT IL2 AXL
6 positive regulation of endothelial cell proliferation GO:0001938 9.61 VEGFA PDCD6 NRAS
7 positive regulation of MAP kinase activity GO:0043406 9.58 VEGFA TNF KIT
8 replicative senescence GO:0090399 9.55 TERT CDKN2A
9 positive regulation of vascular permeability GO:0043117 9.54 VEGFA PTP4A3
10 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.51 VEGFA PLG
11 positive regulation of protein kinase C signaling GO:0090037 9.49 VEGFA MC1R
12 somatic stem cell division GO:0048103 9.48 KIT CDKN2A
13 regulation of vascular endothelial growth factor signaling pathway GO:1900746 9.32 PTP4A3 CD63
14 establishment of protein localization to telomere GO:0070200 9.26 TERT BRCA2
15 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.16 VEGFA PDCD6
16 pigmentation GO:0043473 9.13 MC1R KIT CD63
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.92 VEGFA TNF KIT IL2

Molecular functions related to Ocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.62 VEGFA TNF TERT S100B RFC5 PTP4A3

Sources for Ocular Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....